These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 91053)

  • 41. Sister chromatid exchange in human populations: the effect of smoking, drug treatment, and occupational exposure.
    Lambert B; Bredberg A; McKenzie W; Sten M
    Cytogenet Cell Genet; 1982; 33(1-2):62-7. PubMed ID: 7116939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical lomustine in the treatment of psoriasis.
    Peck GL; Guss SB; Key DJ
    Arch Dermatol; 1972 Aug; 106(2):172-6. PubMed ID: 4558698
    [No Abstract]   [Full Text] [Related]  

  • 43. 1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
    Leoni F; Grossi A; Rossi Ferrini P
    Acta Haematol; 1983; 69(3):180-3. PubMed ID: 6404101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196).
    Chang H; Freireich EJ; Khaliq A; Einhorn L; Gottlieb JA
    Cancer Chemother Rep; 1975; 59(4):769-71. PubMed ID: 1100230
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of geomagnetic activity on mustophoran hematotoxicity.
    Blank MA; Blank OA; Gershanovich ML
    Dokl Biol Sci; 2005; 404():338-40. PubMed ID: 16405109
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
    Berd D; Wilson EJ; Bellet RE; Mastrangelo MJ
    Cancer Res; 1979 Nov; 39(11):4472-6. PubMed ID: 387215
    [No Abstract]   [Full Text] [Related]  

  • 47. Tolerability of metronomic administration of lomustine in dogs with cancer.
    Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
    J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of metastatic testicular carcinoma with bleomycin (NSC-125066) used alone or in combination with CCNU (NSC-79037).
    Sonntag RW; Brunner KW; Batz K; Ryssel HJ
    Cancer Chemother Rep; 1975; 59(2 Pt 1):429-31. PubMed ID: 50125
    [No Abstract]   [Full Text] [Related]  

  • 49. Hematologic complications of cancer chemotherapy.
    Hoagland HC
    Semin Oncol; 1982 Mar; 9(1):95-102. PubMed ID: 7071611
    [No Abstract]   [Full Text] [Related]  

  • 50. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cause of variability in activity of samples of CCNU against P388 leukemia in vivo.
    Montgomery JA
    Cancer Treat Rep; 1980; 64(8-9):987-91. PubMed ID: 7448833
    [No Abstract]   [Full Text] [Related]  

  • 52. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
    Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
    J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
    Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
    J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung.
    Edmonson JH; Lagakos S; Stolbach L; Perlia CP; Bennett JM; Mansour EG; Horton J; Regelson W; Cummings FJ; Israel L; Brodsky I; Shnider BI; Creech R; Carbone PP
    Cancer Treat Rep; 1976 May; 60(5):625-7. PubMed ID: 186183
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
    Seiler RW; Vassella F; Markwalder H
    Surg Neurol; 1979 Mar; 11(3):237-42. PubMed ID: 473022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
    Cedermark BJ; Didolkar MS; Elias EG
    Cancer Treat Rep; 1976 Mar; 60(3):235-8. PubMed ID: 769977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug cause of thrombocytopenia?
    Given WD
    W V Med J; 1988 Apr; 84(4):140. PubMed ID: 3363961
    [No Abstract]   [Full Text] [Related]  

  • 59. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Zander T; Nettekoven W; Kraus JA; Pels H; Ko YD; Vetter H; Klockgether T; Schlegel U
    J Neurol; 2002 Aug; 249(8):1055-7. PubMed ID: 12195453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.